References
- Yalcin N, Bayraktar I, Karabulut E, et al. Is everyone invited to the discussion table? A bibliometric analysis COVID-19-related mental health literature. Glob Ment Health. 2022;9:366–374. doi: 10.1017/gmh.2022.37
- The impact of COVID-19 on mental health cannot be made light of [Internet]. World Health Organization; 2022 [cited 2023 May 18]. Available from: https://www.who.int/news-room/feature-stories/detail/the-impact-of-covid-19-on-mental-health-cannot-be-made-light-of
- Who coronavirus (COVID-19) dashboard, [cited 2023 Oct 19]. Available from: https://covid19.who.int/
- “Long covid or post-covid conditions,” Centers for Disease Control and Prevention, [cited Oct 19 2023]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html
- Covid-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide [Internet]. World Health Organization; 2022 [cited 2023 May 18]. Available from: https://www.who.int/news/item/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression-worldwide
- Sürmelioğlu N, Yalçın N, Kuşçu F, et al. Physicians’ knowledge of potential COVID-19 drug–drug interactions: an online survey in turkey. Postgrad Med. 2021;133(2):237–241. doi: 10.1080/00325481.2020.1807809
- Luykx JJ, van Veen SM, Risselada A, et al. Safe and informed prescribing of psychotropic medication during the COVID-19 pandemic. Br J Psychiatry. 2020;217(3):471–474. doi: 10.1192/bjp.2020.92
- Spina E, Barbieri MA, Cicala G, et al. Clinically relevant interactions between atypical antipsychotics and anti-infective agents. Pharmaceuticals. 2020;13(12):439. doi: 10.3390/ph13120439
- Lenoir C, Terrier J, Gloor Y, et al. Impact of SARS-CoV-2 infection (COVID-19) on Cytochromes P450 activity assessed by the Geneva cocktail. Clin Pharmacol Ther. 2021;110(5):1358–1367. doi: 10.1002/cpt.2412
- Arrojo-Romero M, Codesido-Barcala MR, Leon J. A covid-19 outbreak in a Spanish long-term psychiatric hospital led to infections in 6 clozapine patients: elevations in their plasma clozapine levels. Revista de psiquiatria y salud mental. 2022;15(4):290–292. doi: 10.1016/j.rpsm.2022.06.001
- Isbister GK, Bowe SJ, Dawson A, et al. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42(3):277–285.
- Palleria C, Di Paolo A, Giofrè C, et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci. 2013;18(7):601–610
- Mohebbi N, Talebi A, Moghadamnia M, et al. Drug interactions of psychiatric and COVID-19 medications. Basic Clin Neurosci. 2020;11(2):185–200. doi: 10.32598/bcn.11.covid19.2500.1
- Yalcin N, Allegaert K. COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed. Eur J Clin Pharmacol. 2022;78(10):1697–1701. doi: 10.1007/s00228-022-03370-7
- Niu J, Straubinger RM, Mager DE. Pharmacodynamic drug–drug interactions. Clin Pharmacol Ther. 2019;105(6):1395–1406. doi: 10.1002/cpt.1434.
- Manjhi PK, Kumar R, Priya A, et al. Drug-drug interactions in patients with COVID-19: a retrospective study at a tertiary care hospital in Eastern India. Maedica (Bucur). 2021 Jun;16(2):163–169. doi: 10.26574/maedica.2021.16.2.163
- Sabe M, Dorsaz O, Huguelet P, et al. Toxicity of psychotropic drugs in patients with COVID-19: a systematic review. Gen Hosp Psychiatry. 2021;70:1–9. doi: 10.1016/j.genhosppsych.2021.02.006
- Akhtar Z, Gallagher MM, Yap YG, et al. Prolonged QT predicts prognosis in COVID-19. Pacing Clin Electrophysiol. 2021;44(5):875–882. doi: 10.1111/pace.14232
- Carron J, Sharif Z, Hussein H, et al. Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic. Ir J Med Sci. 2021;190(1):403–409. doi: 10.1007/s11845-020-02291-7
- Pornwattanakavee SP, Priksri W, Leelakanok N. Qtc prolongation in patients with COVID-19: a retrospective chart review. Transl Clin Pharmacol. 2021;29(4):197–205. doi: 10.12793/tcp.2021.29.e20
- Serotonin syndrome: MedlinePlus medical encyclopedia [Internet]. U.S. National Library of Medicine; [cited 2023 May 18]. Available from: https://medlineplus.gov/ency/article/007272
- Boyer EW (2023). Serotonin syndrome (serotonin toxicity). Available from: https://www.uptodate.com/contents/serotonin-syndrome-serotonin-toxicity
- Mas Serrano M, Pérez-Sánchez JR, Portela Sánchez S, et al. Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir. J Neurolog Sci. 2020 Aug 15;415:116944. doi: 10.1016/j.jns.2020.116944
- Keith P, Saint-Jour M, Pusey F, et al. Unprovoked serotonin syndrome-like presentation of SARS-CoV-2 infection: a small case series. SAGE Open Med Case Rep. 2021;9:2050313X211032089. doi: 10.1177/2050313X211032089
- Plasencia-García BO, Rodríguez-Menéndez G, Rico-Rangel MI, et al. Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review. Psychopharmacology. 2021;238(2):329–340. :
- Khatib R, Sabir FRN, Omari C, et al. Managing drug-induced QT prolongation in clinical practice. Postgrad Med J. 2021;97(1149):452–458. doi: 10.1136/postgradmedj-2020-138661
- Tan MS, Heise CW, Gallo T, et al. Relationship between a risk score for QT interval prolongation and mortality across rural and urban inpatient facilities. J Electrocardiol. 2023;77:4–9. doi: 10.1016/j.jelectrocard.2022.11.008
- Su K, McGloin R, Gellatly RM. Predictive validity of a QTc interval prolongation risk score in the intensive care unit. Pharmacother J Human Pharmacol Drug Ther. 2020;40(6):492–499. doi: 10.1002/phar.2400
- Al-Akchar M, Siddique MS. Long QT Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. https://www.ncbi.nlm.nih.gov/books/NBK441860/
- Crescioli G, Brilli V, Lanzi C, et al. Adverse drug reactions in SARS-COV-2 hospitalised patients: a case-series with a focus on drug–drug interactions. Int Emerg Med. 2020;16(3):697–710. doi: 10.1007/s11739-020-02586-8
- Kumar D, Trivedi N. Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2021;139:111642. doi: 10.1016/j.biopha.2021.111642
- Kim GH. Pathophysiology of drug-induced hyponatremia. J Clin Med. 2022;11(19):5810. doi: 10.3390/jcm11195810
- Seifert J, Letmaier M, Greiner T, et al. Psychotropic drug-induced hyponatremia: results from a drug surveillance program–an update. J Neural Transm. 2021;128(8):1249–1264. doi: 10.1007/s00702-021-02369-1
- Gheorghe G, Ilie M, Bungau S, et al. Is there a relationship between COVID-19 and hyponatremia? Medicina. 2021;57(1):55. doi: 10.3390/medicina57010055
- Liu P, Wang L, Han D, et al. Acquired long QT syndrome in chronic kidney disease patients. Ren Fail. 2020;42(1):54–65. doi: 10.1080/0886022X.2019.1707098
- Remdesivir [Internet]. National Institutes of Health. U.S. Department of Health and Human Services; [cited 2023 May 19]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/remdesivir/
- Remdesivir. Highlights of prescribing information [Internet]. Food And Drug Administration; [cited 2023 May 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf
- Deb S, Reeves AA, Hopefl R, et al. ADME and pharmacokinetic properties of remdesivir: its drug interaction potential. Pharmaceuticals. 2021;14(7):655. doi: 10.3390/ph14070655
- Ico G, Isayeva U, De Prisco M, et al. Psychotropic drug repurposing for COVID-19: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2023;66:30–44. doi: 10.1016/j.euroneuro.2022.10.004
- Janus kinase inhibitors. COVID-19 treatment guidelines [Internet]. National Institutes of Health. U.S. Department of Health and Human Services; [cited 2023 May 19]. Available from: http://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/janus-kinase-inhibitors/
- Ely EW, Ramanan AV, Kartman CE, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10(4):327–336.
- Selvaraj V, Finn A, Lal A, et al. Baricitinib in hospitalised patients with covid-19: a meta-analysis of randomised controlled trials. eClinicalmedicine. 2022 Jun 3;49:101489. doi: 10.1016/j.eclinm.2022.101489
- Hodge D, Marra F, Marzolini C, et al. Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. J Antimicrob Chemother. 2020 Aug 4;75(12):3417–3424. doi: 10.1093/jac/dkaa340
- Plasencia-García BO, Rodríguez-Menéndez G, Rico-Rangel MI. Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review. Psychopharmacology (Berl). 2021;238(2):329–340. doi: 10.1007/s00213-020-05716-4
- Interleukin-1 inhibitors. COVID-19 treatment guidelines [Internet]. National Institutes of health. U.S. Department of Health and Human Services; [cited 2023 May 19]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/interleukin-1-inhibitors/
- Khani E, Shahrabi M, Rezaei H, et al. Current evidence on the use of Anakinra in covid-19. Int Immunopharmacol. 2022 Jul 20;111:109075. doi: 10.1016/j.intimp.2022.109075
- Anakinra. Highlights of prescribing information [Internet]. Food and Drug Administration; [cited 2023 May 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103950s5136lbl.pdf
- Sernoskie SC, Lobach AR, Kato R, et al. Clozapine Induces an Acute Proinflammatory Response That Is Attenuated by Inhibition of Inflammasome Signaling: Implications for Idiosyncratic Drug-Induced Agranulocytosis. Toxicol Sci. 2022;186(1):70–82. doi: 10.1093/toxsci/kfab154
- Lam C, Patel PN [Updated 2022 Nov 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK585126/
- Fedder D, Patel H, Saadabadi A. Atomoxetine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan [2023 Mar 27]. https://www.ncbi.nlm.nih.gov/books/NBK493234/
- Hodgson SE, Harding AM, Bourke EM, et al. A prospective, randomized, double‐blind trial of intravenous chlorpromazine versus intravenous prochlorperazine for the treatment of acute migraine in adults presenting to the emergency department. Headache. 2021;61(4):603–611.
- Wenzel-Seifert K, Wittmann M, Haen E. Qtc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int. 2011;108(41):687–693. doi: 10.3238/arztebl.2011.0687
- Lu Z, Zhang Y, Yan H, et al. ATAD3B and SKIL polymorphisms associated with antipsychotic-induced QTc interval change in patients with schizophrenia: a genome-wide association study. Transl Psychiatry. 2022;12(1):56. doi: 10.1038/s41398-022-01825-0
- Thour A, Marwaha R. Amitriptyline. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [2023 Jul 18]. https://www.ncbi.nlm.nih.gov/books/NBK537225/
- Dean L. Imipramine Therapy and CYP2D6 and CYP2C19 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2017. https://www.ncbi.nlm.nih.gov/books/NBK425164/
- Samaee H, Mohsenzadegan M, Ala S, et al. Tocilizumab for treatment patients with COVID-19: recommended medication for novel disease. Int Immunopharmacol. 2020;89:107018. doi: 10.1016/j.intimp.2020.107018
- Sheppard M, Laskou F, Stapleton PP, et al. Tocilizumab (Actemra). Human Vaccines Immunother. 2017 Jul 25;13(9):1972–1988. doi: 10.1080/21645515.2017.1316909
- Shovman O, Shoenfeld Y, Langevitz P. Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: case series and review of literature. Immunol Res. 2015;61(1–2):164–8. doi: 10.1007/s12026-014-8590-4
- Yip AJ, Low ZY, Chow VT, et al. Repurposing molnupiravir for covid-19: the mechanisms of antiviral activity. Viruses. 2022 Jun 20;14(6):1345. doi: 10.3390/v14061345
- National Institute of Health- Covid-19 Treatment Guidelines. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/molnupiravir/
- White C, Scott R, Paul CL, et al. Pharmacogenomics in the era of personalised medicine. Med j Aust. 2022;217(10):510. doi: 10.5694/mja2.51759
- Cecchin E, Stocco G. Pharmacogenomics and personalized Medicine. Genes. 2020;11(6):679. doi: 10.3390/genes11060679
- Hahn M, Roll SC. The influence of pharmacogenetics on the clinical relevance of pharmacokinetic drug-drug interactions: drug-Gene, drug-Gene-Gene and drug-drug-Gene interactions. Pharmaceuticals. 2021;14(5):487. doi: 10.3390/ph14050487
- Blanco-González A, Cabezón A, Seco-González A, et al. The role of AI in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals. 2023;16(6):891. doi: 10.3390/ph16060891
- Vo TH, Nguyen NTK, Kha QH, et al. On the road to explainable AI in drug-drug interactions prediction: a systematic review. Computat Struct Biotechnol J. 2022;20:2112–2123